(Q40791108)

23 September 2017

1 reference

title

Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview (English)

1 reference

23 September 2017

1 reference

1 reference

1 reference

R J MacFadyen

1

1 reference

23 September 2017

P A Meredith

series ordinal

2

1 reference

23 September 2017

H L Elliott

series ordinal

3

1 reference

23 September 2017

1 October 1993

1 reference

Clinical Pharmacokinetics

23 September 2017

1 reference

23 September 2017

25

1 reference

23 September 2017

274-282

1 reference

23 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199325040-00003

23 September 2017

0 references

cites work

The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure

1 reference

12 December 2020

Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function

1 reference

12 December 2020

1 reference

12 December 2020

Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers

1 reference

12 December 2020

Concentration-effect analysis of antihypertensive drug responses

1 reference

12 December 2020

Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding

1 reference

12 December 2020

Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model

1 reference

12 December 2020

Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension

1 reference

12 December 2020

Enalapril (MK421) activation in man: importance of liver status

1 reference

12 December 2020

Kinetics and dynamics of enalapril in patients with liver cirrhosis

1 reference

12 December 2020

The pharmacokinetics of enalapril in patients with compensated liver cirrhosis

1 reference

12 December 2020

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

12 December 2020

Enalapril maleate and a lysine analogue (MK-521): disposition in man

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension

1 reference

12 December 2020

Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat

1 reference

12 December 2020

Kinetic-dynamic relations and individual responses to enalapril

1 reference

12 December 2020

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

12 December 2020

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

12 December 2020

Prediction of the antihypertensive response to enalapril

1 reference

12 December 2020

Enalapril pharmacokinetics in diabetic patients

1 reference

12 December 2020

Angiotensin-converting enzyme: new concepts concerning its biological role

1 reference

12 December 2020

Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans

1 reference

12 December 2020

Clinical pharmacology of enalapril

1 reference

12 December 2020

Determinants of angiotensin II generation during converting enzyme inhibition

1 reference

12 December 2020

The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure

1 reference

12 December 2020

Captopril and the diuretic requirements in moderate and severe chronic heart failure

1 reference

12 December 2020

An overview of the clinical pharmacology of enalapril

1 reference

12 December 2020

Pharmacokinetics of repeated single oral doses of enalapril maleate (mk-421) in normal volunteers

1 reference

12 December 2020

Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure

1 reference

12 December 2020

Enalapril Worldwide Experience

1 reference

12 December 2020

Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects

1 reference

12 December 2020

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

1 reference

12 December 2020

Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects

1 reference

12 December 2020

Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man

1 reference

12 December 2020

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

12 December 2020

Influence of Food on the Bioavailability of Enalapril

1 reference

12 December 2020

Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension

1 reference

12 December 2020

Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats

1 reference

12 December 2020

10.2165/00003088-199325040-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

23 September 2017

0 references

1 reference